224 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1221)
- Addiction (16)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (18)
- Bone & Muscle (10)
- Cancer (102)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (48)
- Insomnia (3)
- Kidney Disease (12)
- Liver Disease (52)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (126)
- Nutrition (5)
- Obesity (9)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (98)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (45)
- Urology (3)
- Vascular Conditions (10)
Displaying 1 - 8 of 8
Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Condition: Cancer / Brain Cancer
Investigator: Mikhail Doubrovin, MD
Status: Closed
The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted…
Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Condition: Cancer / Brain Cancer
Investigator: Stergios Zacharoulis, MD
Status: Closed
Children and young adults with diffuse midline glioma will be treated with Focused Ultrasound (FUS) with DEFINITY microbubbles and neuro-navigator-controlled sonication. The overall goal of this study is to see if the study treatment plan will improve the outcome of participants with diffuse midline glioma, for which no known cure exists, and determine…
Condition: Cancer / Brain Cancer
Investigator: James Hinkley Garvin Jr, MD
Status: Closed
The purpose of this study is to find the best dose of a drug called MTX110 and a contrast agent called gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas, which is a kind of brain tumor. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: David Lederer, MD
Status: Closed
The purpose of this study is to study the effects of a new study drug known as Riociguat in people diagnosed with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Patients will be in the study for approximately 26 weeks in which they will take the pill Riogciguat three times a day.
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Erika Berman-Rosenzweig, MD
Status: Closed
This is a clinical research study designed to determine the safety and effectiveness of the TIVUS system, an investigational device used in the treatment of PAH. The TIVUS System is intended to treat patients with pulmonary artery hypertension by injuring the sympathetic nerves surrounding the pulmonary vasculature (denervation) using ultrasonic energy. The…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Elana Bernstein, MD
Status: Closed
This study involves two infusions of either rituximab or placebo, two right heart catheterizations (6 months apart), and a variety of other clinical study procedures and exams.